BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
BRM.DE Key Statistics, Chart & Performance
The current stock price of BRM.DE is 44.745 EUR. In the past month the price increased by 10.73%. In the past year, price decreased by -16.11%.
BRM.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.98 | 202.68B | ||
| SAN.PA | SANOFI | 10.96 | 202.38B | ||
| 1SAN.MI | SANOFI | 10.85 | 200.32B | ||
| MRK.DE | MERCK KGAA | 13.82 | 51.24B | ||
| UNC.DE | UCB SA | 36.62 | 45.73B | ||
| UCB.BR | UCB SA | 36.65 | 45.77B | ||
| 1BAYN.MI | BAYER AG-REG | 6.78 | 35.56B | ||
| BAYN.DE | BAYER AG-REG | 6.84 | 35.86B | ||
| IPN.PA | IPSEN | 11.79 | 10.15B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.47 | 10.08B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 102.88 | 9.53B | ||
| VIRP.PA | VIRBAC SA | 19.55 | 2.84B |
Related stock screener links
About BRM.DE
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What does BRM do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the current price of BRM stock?
The current stock price of BRM.DE is 44.745 EUR. The price increased by 2.61% in the last trading session.
Does BRISTOL-MYERS SQUIBB CO pay dividends?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 4.92%. The yearly dividend amount is currently 2.06.
What is the ChartMill technical and fundamental rating of BRM stock?
BRM.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is BRM.DE stock listed?
BRM.DE stock is listed on the Frankfurt Stock Exchange exchange.
Should I buy BRM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BRM.DE.
What is the market capitalization of BRM stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 91.09B EUR. This makes BRM.DE a Large Cap stock.
BRM.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BRM.DE. When comparing the yearly performance of all stocks, BRM.DE is a bad performer in the overall market: 71.78% of all stocks are doing better.
BRM.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE. Both the profitability and the financial health of BRM.DE get a neutral evaluation. Nothing too spectacular is happening here.
BRM.DE Financial Highlights
Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 5.6. The EPS increased by 460.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
BRM.DE Forecast & Estimates
34 analysts have analysed BRM.DE and the average price target is 45.88 EUR. This implies a price increase of 2.53% is expected in the next year compared to the current price of 44.745.
For the next year, analysts expect an EPS growth of 479.55% and a revenue growth 0.19% for BRM.DE